LimmaTech Biologics
Founded 2015 · 57 employees on LinkedIn · 5 known investors
Find your way into LimmaTech Biologics
LimmaTech develops vaccine technologies and programs designed to combat antimicrobial-resistant pathogens and prevent severe infections. The company uses proprietary vaccine platform technology and engineered microorganisms to create vaccine solutions addressing emerging infectious diseases and antimicrobial resistance.
Investors · 5
Also in the syndicate · 2
AXA IM AltsleadNovo Holdings REPAIR Impact Fundlead
Funding
SEC filings, press & company announcements$3M disclosed across 1 of 2 rounds · 2023–2024
- $3MSeries AFeb 2024 · 2 sources
Adjuvant Capital (lead), AXA IM Alts (lead), Novo Holdings REPAIR Impact Fund (lead), Tenmile
Source ↗ - Undisclosed amountSeries AOct 2023Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does LimmaTech Biologics do?
- LimmaTech develops vaccine technologies and programs designed to combat antimicrobial-resistant pathogens and prevent severe infections. The company uses proprietary vaccine platform technology and engineered microorganisms to create vaccine solutions addressing emerging infectious diseases and antimicrobial resistance.
- Who are LimmaTech Biologics's investors?
- LimmaTech Biologics's investors include Adjuvant Capital, Andera Partners, Tenmile.
- How much funding has LimmaTech Biologics raised?
- LimmaTech Biologics has disclosed $3M raised across 1 of its 2 known rounds.